UBS Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-44,288
| Closed | -$442K | – | 10603 |
|
|
2025
Q2 | $442K | Buy |
44,288
+18,028
| +69% | +$145K | ﹤0.01% | 6114 |
|
|
2025
Q1 | $157K | Sell |
26,260
-66,901
| -72% | -$491K | ﹤0.01% | 6718 |
|
|
2024
Q4 | $715K | Buy |
93,161
+49,396
| +113% | +$424K | ﹤0.01% | 5590 |
|
|
2024
Q3 | $447K | Buy |
43,765
+14,379
| +49% | +$219K | ﹤0.01% | 5310 |
|
|
2024
Q2 | $436K | Sell |
29,386
-29,708
| -50% | -$426K | ﹤0.01% | 5102 |
|
|
2024
Q1 | $806K | Buy |
59,094
+13,810
| +30% | +$150K | ﹤0.01% | 4772 |
|
|
2023
Q4 | $496K | Buy |
45,284
+22,158
| +96% | +$220K | ﹤0.01% | 5119 |
|
|
2023
Q3 | $253K | Sell |
23,126
-21,589
| -48% | -$276K | ﹤0.01% | 5199 |
|
|
2023
Q2 | $592K | Buy |
44,715
+1,068
| +2% | +$15.2K | ﹤0.01% | 4681 |
|
|
2023
Q1 | $594K | Sell |
43,647
-47,218
| -52% | -$846K | ﹤0.01% | 4558 |
|
|
2022
Q4 | $1.77M | Buy |
90,865
+23,027
| +34% | +$450K | ﹤0.01% | 3514 |
|
|
2022
Q3 | $1.29M | Sell |
67,838
-90,366
| -57% | -$2.08M | ﹤0.01% | 3530 |
|
|
2022
Q2 | $3.26M | Sell |
158,204
-12,486
| -7% | -$296K | ﹤0.01% | 2729 |
|
|
2022
Q1 | $5.49M | Buy |
170,690
+132,934
| +352% | +$4.83M | ﹤0.01% | 2443 |
|
|
2021
Q4 | $1.76M | Buy |
37,756
+37,621
| +27,867% | +$1.25M | ﹤0.01% | 3849 |
|
|
2021
Q3 | $4K | Sell |
135
-2,749
| -95% | -$71.9K | ﹤0.01% | 8647 |
|
|
2021
Q2 | $74K | Sell |
2,884
-9,641
| -77% | -$230K | ﹤0.01% | 6102 |
|
|
2021
Q1 | $428K | Buy |
12,525
+8,919
| +247% | +$322K | ﹤0.01% | 4987 |
|
|
2020
Q4 | $122K | Buy |
+3,606
| New | +$95.5K | ﹤0.01% | 5558 |
|
Other funds holding ITOS
UBS Group's ITOS Position: Q3 2025 in Review
UBS Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 44,288 shares — an estimated $442K sold.
UBS Group first reported a position in ITOS in Q4 2020 and held it in 19 quarters. The position peaked at $5.49M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- UBS Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- UBS Group sold 44,288 iTeos Therapeutics shares in Q3 2025, an estimated $442K.
- UBS Group first reported a position in iTeos Therapeutics in Q4 2020 and held it in 19 quarters.
- UBS Group's iTeos Therapeutics position peaked at $5.49M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.